Business Expansion Through Acquisition of a Veterinary Hospital Management Business
First written in FY2020-Q2. 21 of 22 entries say "Advanced", first in FY2021-Q1. Latest entry: 2026-08-07.
1 other company's latest entry also says "Advanced".
- 2026-08-07AdvancedFinancial results presentation
「“JARVIS Animal Medical Center Tokyo” drove revenue growth, with revenue at 120% of the previous year's level. We expect further expansion through an increase in cases and the capture of demand for advanced medical care.」
In the animal hospital operations business, JARVIS Tokyo drove revenue growth, with first-quarter revenue for the business totaling ¥820 million, or 120% of the previous year's level. The disclosure also referred to closures and downsizing at existing hospitals. - FY2026AdvancedAnnual report
「Ordinary revenue from the veterinary hospital operations business was ¥2,401 million, an increase of ¥231 million, or 10.7%, year on year. アニコム先進医療研究所株式会社 promotes basic research in animal healthcare, establishes evidence-based treatment methods, and conducts research, clinical work and development aimed at developing preventive and advanced medical care, while also taking over veterinary hospitals to support regional veterinary care.」
Ordinary revenue from the veterinary hospital operations business was ¥2,401 million, up 10.7% from the previous fiscal year. JARVISどうぶつ医療センター Tokyo is being developed as an advanced medical care hub for secondary care and emergency services at night. - FY2026-H1AdvancedAnnual report
「Ordinary revenue from the veterinary hospital operations business was ¥1,221 million, an increase of ¥58 million, or 5.1%, year on year.」
The veterinary hospital operations business was disclosed as a separate reporting segment, with ordinary revenue of ¥1,221 million, up 5.1% year on year. - FY2025AdvancedAnnual report
「アニコム先進医療研究所株式会社's veterinary hospital business currently comprises 58 hospitals, which provide a wide range of medical services, from preventive care to regenerative medicine.」
The number of company-operated veterinary hospitals increased from 54 to 58. The number of hospitals participating in the Regenerative Medicine Technology Research Association was 809, and 492 stem-cell treatments were administered in fiscal 2024. - FY2025-H1AdvancedAnnual report
「At アニコム先進医療研究所株式会社, we promoted basic research in animal healthcare, established evidence-based treatment methods, and conducted research, clinical work and development aimed at developing preventive and advanced medical care, while also taking over veterinary hospitals to support regional veterinary care. As a result, ordinary revenue for the six months ended 30 September was ¥1,264 million, up 20.4% year on year.」
The company continued its hospital takeovers, basic research, clinical work and development, and preventive and advanced medical care initiatives. Ordinary revenue in the animal healthcare business was ¥1,264 million, up 20.4% year on year. - FY2024-Q3AdvancedAnnual report
「At アニコム先進医療研究所株式会社, we promoted basic research in animal healthcare, established evidence-based treatment methods, and conducted research, clinical work and development aimed at developing preventive and advanced medical care, while also taking over veterinary hospitals to support regional veterinary care. As a result, ordinary revenue for the nine months ended 31 December was ¥1,525 million, up 7.8% year on year.」
The company continued its hospital takeovers, basic research, clinical work and development, and preventive and advanced medical care initiatives. Ordinary revenue in the animal healthcare business was ¥1,525 million, up 7.8% year on year. - FY2024-Q2AdvancedAnnual report
「アニコム先進医療研究所株式会社 conducted basic research in animal healthcare, established evidence-based treatment methods, and carried out research, clinical work, and development aimed at preventive and advanced medical care, while also taking over hospitals to support regional veterinary care. As a result, ordinary revenue for the cumulative second-quarter consolidated period was ¥1,049 million, up 6.3% year on year.」
Hospital succession, basic research, clinical work and development, and preventive and advanced medical care continued, and ordinary revenue from the animal healthcare field was ¥1,049 million, up 6.3% year on year. - FY2024-Q1AdvancedAnnual report
「アニコム先進医療研究所株式会社 conducted basic research in animal healthcare, established evidence-based treatment methods, and carried out research, clinical work, and development aimed at preventive and advanced medical care, while also taking over hospitals to support regional veterinary care. As a result, ordinary revenue for the cumulative first-quarter consolidated period was ¥574 million, up 5.0% year on year. アニコム先進医療研究所株式会社 operates veterinary hospitals itself and provides primary and secondary care ranging from preventive services. It aims to establish next-generation preventive methods by using medical and other data obtained through these activities.」
Hospital succession, basic research, clinical work and development, and preventive and advanced medical care continued, and ordinary revenue from the animal healthcare field was ¥574 million, up 5.0% year on year. The policy of using medical data to establish next-generation preventive methods also continued. - FY2023AdvancedAnnual report
「The 動物再生医療技術研究組合, established under the leadership of Anicom Group to promote the adoption of regenerative medicine, had 637 member veterinary hospitals as of the end of March 2023 and achieved more than 350 stem-cell administration procedures in fiscal 2022. The Group aims to expand the diseases eligible for regenerative medicine and introduce new technologies.」
The number of hospitals belonging to 動物再生医療技術研究組合 reached 637, while stem-cell administration procedures exceeded 350 in fiscal 2022, giving concrete form to the rollout of advanced medical care. - FY2023-Q3AdvancedAnnual report
「アニコム先進医療研究所株式会社 conducted basic research in animal healthcare, established evidence-based treatment methods, and carried out research, clinical work, and development aimed at preventive and advanced medical care, while also taking over hospitals to support regional veterinary care. As a result, ordinary revenue for the cumulative third-quarter consolidated period was ¥1,414 million, up 11.9% year on year.」
Hospital succession, basic research, clinical work and development, and preventive and advanced medical care continued, and ordinary revenue from the animal healthcare field was ¥1,414 million, up 11.9% year on year. The policy of using medical data obtained at the Group's own hospitals to establish next-generation preventive methods also continued. - FY2023-Q2AdvancedAnnual report
「アニコム先進医療研究所株式会社 conducted basic research in animal healthcare, established evidence-based treatment methods, and carried out research, clinical work, and development aimed at preventive and advanced medical care, while also taking over hospitals to support regional veterinary care. As a result, ordinary revenue for the cumulative second-quarter consolidated period was ¥987 million, up 14.7% year on year.」
Hospital succession, basic research, clinical work and development, and preventive and advanced medical care continued, and ordinary revenue from the animal healthcare field was ¥987 million, up 14.7% year on year. - FY2023-Q1AdvancedAnnual report
「アニコム先進医療研究所株式会社 conducted basic research in animal healthcare, established evidence-based treatment methods, and carried out research, clinical work, and development aimed at preventive and advanced medical care, while also taking over hospitals to support regional veterinary care. As a result, ordinary revenue for the cumulative first-quarter consolidated period was ¥546 million, up 15.6% year on year.」
Hospital succession, basic research, clinical work and development, and preventive and advanced medical care continued, and ordinary revenue from clinical and research operations in the animal healthcare field was ¥546 million, up 15.6% year on year. - FY2022-Q3AdvancedAnnual report
「アニコム先進医療研究所株式会社 conducted basic research in animal healthcare, established evidence-based treatment methods, and carried out research, clinical work, and development aimed at preventive and advanced medical care, while also taking over hospitals to support regional veterinary care. As a result, ordinary revenue for the cumulative third-quarter consolidated period was ¥1,264 million, up 16.9% year on year. アニコム先進医療研究所株式会社 operates veterinary hospitals itself and provides primary and secondary care ranging from preventive services. It aims to establish next-generation preventive methods by using medical and other data obtained through these activities.」
Hospital succession, basic research, clinical work and development, and preventive and advanced medical care continued, and ordinary revenue from research and clinical operations in the animal healthcare field was ¥1,264 million, up 16.9% year on year. The policy of using medical data to establish next-generation preventive methods also continued. - FY2022-Q2AdvancedAnnual report
「アニコム先進医療研究所株式会社 conducted basic research in animal healthcare, established evidence-based treatment methods, and carried out research, clinical work, and development aimed at preventive and advanced medical care, while also taking over hospitals to support regional veterinary care. As a result, ordinary revenue for the cumulative second-quarter consolidated period was ¥860 million, up 17.0% year on year.」
Research and clinical operations in the animal healthcare field, including hospital succession, continued, and ordinary revenue was ¥860 million, up 17.0% year on year. - FY2022-Q1AdvancedAnnual report
「アニコム先進医療研究所株式会社 conducted basic research in animal healthcare, established evidence-based treatment methods, and carried out research, clinical work, and development aimed at preventive and advanced medical care, while also taking over hospitals to support regional veterinary care. As a result, ordinary revenue for the cumulative first-quarter consolidated period was ¥473 million, up 23.9% year on year.」
Research and clinical operations in the animal healthcare field, including hospital succession, continued, and ordinary revenue was ¥473 million, up 23.9% year on year. - FY2021AdvancedAnnual report
「The Group also operates veterinary hospitals itself and has expanded the network to 54 hospitals. These hospitals provide a range of medical services, from preventive care to regenerative medicine. As it develops and expands its veterinary hospital business, the Group plans to increase the number of hospitals using its medical records management system, leverage the medical and insurance claims data obtained through those hospitals, and establish next-generation preventive methods.」
The number of veterinary hospitals operated directly by the Group increased to 54, offering services from preventive care to regenerative medicine, while the Group developed its plan to use medical and insurance claims data in establishing next-generation preventive methods. - FY2021-Q3AdvancedAnnual report
「アニコム先進医療研究所株式会社 conducted basic research in animal healthcare, established evidence-based treatment methods, and carried out research, clinical work, and development aimed at preventive and advanced medical care, while also taking over hospitals to support regional veterinary care. As a result, ordinary revenue for the cumulative third-quarter consolidated period was ¥1,081 million, up 75.3% year on year.」
Research and clinical operations in the animal healthcare field, including hospital succession, continued, and ordinary revenue was ¥1,081 million, up 75.3% year on year. - FY2021-Q2AdvancedAnnual report
「アニコム先進医療研究所株式会社 conducted basic research in animal healthcare, established evidence-based treatment methods, and carried out research, clinical work, and development aimed at preventive and advanced medical care, while also taking over hospitals to support regional veterinary care. As a result, ordinary revenue for the cumulative second-quarter consolidated period was ¥735 million, up 116.0% year on year.」
Research and clinical operations in the animal healthcare field, including hospital succession, continued, and ordinary revenue was ¥735 million, up 116.0% year on year. - FY2021-Q1AdvancedAnnual report
「As a result of taking over hospitals to support regional veterinary care, ordinary revenue for the first quarter of the current cumulative consolidated period was ¥381 million, up 111.3% year on year.」
The Group advanced its support for regional veterinary care through hospital succession, and ordinary revenue from research and clinical operations in the animal healthcare field was ¥381 million, up 111.3% year on year. - FY2020-Q2First statedAnnual report
「The Group decided to acquire the veterinary hospital management business from ㈲梅島動物病院 and acquired the business on 30 September 2019. The purpose was to expand the Group's veterinary hospital management business. Consideration for acquisition: Cash ¥414 million Acquisition cost: ¥414 million」
To expand its veterinary hospital management business, the Group acquired the business from ㈲梅島動物病院 on 30 September 2019. The acquisition cost was ¥414 million, including ¥350 million in goodwill, which is being amortized on a straight-line basis over 10 years.